PriceTargets.com logo

Encompass Health - EHC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $69.00
  • Forecasted Upside: 27.54%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$54.10 As of 03/31/2023 01:00 AM ET
▲ +1.12 (2.11%)

This chart shows the closing price for EHC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Encompass Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EHC

Analyst Price Target is $69.00
▲ +27.54% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Encompass Health in the last 3 months. The average price target is $69.00, with a high forecast of $75.00 and a low forecast of $57.00. The average price target represents a 27.54% upside from the last price of $54.10.

This chart shows the closing price for EHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Encompass Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2021
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2022
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2022
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2022
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2022
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2022
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2023
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2023

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2023BarclaysInitiated CoverageEqual Weight$57.00Low
2/9/2023Deutsche Bank AktiengesellschaftBoost Target$62.00 ➝ $70.00Low
2/9/2023Truist FinancialBoost TargetBuy$70.00 ➝ $75.00Low
2/9/2023MizuhoBoost TargetBuy$65.00 ➝ $69.00Low
2/9/2023Credit Suisse GroupBoost TargetOutperform$62.00 ➝ $73.00Low
2/8/2023UBS GroupBoost Target$68.00 ➝ $73.00Low
2/8/2023StephensReiterated RatingOverweight$70.00Low
10/28/2022StephensLower TargetOverweight$60.00 ➝ $58.00Low
10/28/2022Raymond JamesBoost TargetStrong-Buy$65.00 ➝ $72.00Low
9/21/2022Credit Suisse GroupLower TargetOutperform$63.00 ➝ $62.00Low
8/24/2022Royal Bank of CanadaLower Target$82.00 ➝ $66.00Low
8/9/2022Credit Suisse GroupLower Target$63.00N/A
8/8/2022Truist FinancialLower TargetBuy$75.00 ➝ $65.00Low
8/4/2022Raymond JamesLower TargetStrong-Buy$70.00 ➝ $65.00Low
8/4/2022BMO Capital MarketsLower TargetOutperform$83.00 ➝ $65.00Low
8/4/2022BarclaysLower TargetOverweight$80.00 ➝ $63.00Low
8/3/2022Deutsche Bank AktiengesellschaftLower Target$80.00 ➝ $62.00Low
6/21/2022Truist FinancialLower TargetBuy$85.00 ➝ $75.00Low
6/21/2022StephensLower TargetOverweight$78.00 ➝ $74.00Low
6/17/2022Raymond JamesLower Target$85.00 ➝ $70.00High
6/10/2022Credit Suisse GroupLower TargetOutperform$83.00 ➝ $82.00Low
6/8/2022Royal Bank of CanadaLower Target$85.00 ➝ $82.00High
4/7/2022Truist FinancialBoost Target$78.00 ➝ $85.00Medium
2/7/2022Raymond JamesLower TargetStrong-Buy$90.00 ➝ $80.00Low
2/3/2022Credit Suisse GroupLower Target$84.00 ➝ $77.00Medium
1/20/2022Deutsche Bank AktiengesellschaftLower Target$95.00 ➝ $80.00High
11/3/2021MizuhoLower TargetBuy$94.00 ➝ $80.00Medium
11/2/2021Raymond JamesLower TargetStrong-Buy$107.00 ➝ $90.00Medium
11/1/2021BMO Capital MarketsLower TargetOutperform$102.00 ➝ $75.00Low
10/29/2021Deutsche Bank AktiengesellschaftLower TargetBuy$110.00 ➝ $95.00Low
10/13/2021Truist FinancialLower TargetBuy$100.00 ➝ $88.00Medium
9/23/2021UBS GroupInitiated CoverageBuy$98.00Low
8/2/2021Raymond JamesUpgradeOutperform ➝ Strong-Buy$95.00 ➝ $107.00Medium
7/29/2021Royal Bank of CanadaBoost TargetOutperform$102.00 ➝ $104.00Low
7/29/2021Credit Suisse GroupBoost TargetOutperform$96.00 ➝ $98.00Medium
7/29/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$104.00 ➝ $110.00Medium
7/2/2021Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$87.00 ➝ $104.00High
4/29/2021Raymond JamesBoost TargetOutperform$90.00 ➝ $95.00Low
4/29/2021MizuhoBoost TargetBuy$90.00 ➝ $94.00N/A
1/28/2021Credit Suisse GroupLower TargetOutperform$97.00 ➝ $92.00Low
1/28/2021Deutsche Bank AktiengesellschaftBoost TargetHold$70.00 ➝ $87.00N/A
1/15/2021UBS GroupBoost TargetBuy$85.00 ➝ $106.00N/A
12/18/2020MizuhoBoost TargetBuy$87.00 ➝ $90.00N/A
11/30/2020Raymond JamesBoost TargetOutperform$78.00 ➝ $90.00Low
11/23/2020BarclaysUpgradeOverweight$96.00Low
11/2/2020Credit Suisse GroupLower TargetOutperform$89.00 ➝ $85.00Medium
11/2/2020Raymond JamesLower TargetOutperform$86.00 ➝ $78.00Low
10/30/2020Deutsche Bank AktiengesellschaftLower TargetHold$83.00 ➝ $70.00N/A
9/10/2020Credit Suisse GroupReiterated RatingBuyN/A
7/27/2020Jefferies Financial GroupLower TargetBuy$90.00 ➝ $86.00Medium
6/10/2020Credit Suisse GroupReiterated RatingBuy$89.00N/A
5/29/2020MizuhoLower TargetBuy$90.00 ➝ $87.00N/A
5/1/2020UBS GroupLower TargetBuy$96.00 ➝ $90.00Low
4/30/2020Raymond JamesLower TargetOutperform$90.00 ➝ $86.00High
4/20/2020Royal Bank of CanadaReiterated RatingBuy$84.00N/A
4/20/2020BMO Capital MarketsBoost TargetOutperform$66.00 ➝ $83.00N/A
4/17/2020Credit Suisse GroupReiterated RatingBuy$89.00N/A
3/6/2020UBS GroupBoost TargetBuy$95.00 ➝ $96.00Medium
3/6/2020Deutsche Bank AktiengesellschaftBoost TargetHold$73.00 ➝ $83.00Low
3/5/2020Robert W. BairdBoost TargetOutperform$85.00 ➝ $100.00High
3/5/2020MizuhoBoost TargetBuy$87.00 ➝ $90.00Low
3/5/2020BMO Capital MarketsBoost TargetOutperform$88.00 ➝ $95.00N/A
3/5/2020StephensBoost TargetOverweight$91.00 ➝ $100.00Low
2/10/2020Piper SandlerBoost Target$77.00 ➝ $89.00N/A
2/10/2020SunTrust BanksBoost TargetBuy$90.00 ➝ $100.00Medium
2/10/2020MizuhoBoost TargetBuy$84.00 ➝ $87.00Medium
2/10/2020MizuhoReiterated RatingBuy$84.00 ➝ $87.00N/A
1/22/2020JMP SecuritiesBoost TargetOutperform$85.00N/A
1/16/2020MizuhoReiterated RatingBuy$76.00 ➝ $84.00N/A
1/15/2020Credit Suisse GroupBoost TargetOutperform$77.00 ➝ $89.00Medium
1/14/2020BMO Capital MarketsBoost TargetOutperform$85.00 ➝ $88.00Medium
1/13/2020Jefferies Financial GroupBoost Target$80.00 ➝ $90.00N/A
1/10/2020UBS GroupBoost TargetBuy$80.00 ➝ $87.00High
12/11/2019Wells Fargo & CompanyDowngradeMarket Perform ➝ Underperform$68.00N/A
10/21/2019StephensInitiated CoverageOverweight$77.00N/A
9/17/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$70.00Low
9/16/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$70.00N/A
9/6/2019Bank of AmericaUpgradeBuyLow
8/12/2019Craig HallumReiterated RatingBuy$81.00 ➝ $76.00N/A
8/7/2019Royal Bank of CanadaReiterated RatingBuyN/A
7/31/2019Piper Jaffray CompaniesSet TargetBuy$77.00N/A
7/31/2019Raymond JamesLower TargetOutperform$80.00 ➝ $75.00Medium
6/27/2019BMO Capital MarketsInitiated CoverageOutperform$72.00High
5/30/2019BarclaysUpgradeEqual Weight ➝ Overweight$68.00 ➝ $70.00Low
12/20/2018Jefferies Financial GroupInitiated CoverageBuy ➝ BuyMedium
12/14/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$75.00High
11/15/2018UBS GroupInitiated CoverageBuy$86.00Medium
7/26/2018MizuhoReiterated RatingBuy$82.00Low
7/26/2018Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightLow
7/26/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$66.00 ➝ $80.00Low
7/20/2018SunTrust BanksReiterated RatingBuy$82.00N/A
4/30/2018Royal Bank of CanadaBoost TargetOutperform$69.00Medium
4/30/2018Robert W. BairdBoost TargetOutperform$59.00 ➝ $66.00Medium
4/30/2018Craig HallumBoost TargetBuy$63.00 ➝ $71.00Medium
4/30/2018Craig HallumReiterated RatingBuy$63.00 ➝ $71.00N/A
4/30/2018Robert W. BairdReiterated RatingOutperform$59.00 ➝ $66.00N/A
4/27/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$65.00 ➝ $66.00Medium
4/17/2018SunTrust BanksReiterated RatingBuy$70.00Low
(Data available from 4/1/2018 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/3/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 11 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2023
  • 13 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/2/2023
  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Encompass Health logo
Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through the Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations. The Home Health and Hospice segment provides Medicare-certified home nursing, specialized home care and in-home services. The company was founded by Richard M. Scrushy on February 22, 1984, and is headquartered in Birmingham, AL.
Read More

Today's Range

Now: $54.10
Low: $53.25
High: $54.12

50 Day Range

MA: $57.81
Low: $51.55
High: $63.21

52 Week Range

Now: $54.10
Low: $44.33
High: $74.61

Volume

982,162 shs

Average Volume

942,348 shs

Market Capitalization

$5.40 billion

P/E Ratio

20.04

Dividend Yield

1.14%

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Encompass Health?

The following sell-side analysts have issued stock ratings on Encompass Health in the last twelve months: Barclays PLC, BMO Capital Markets, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Mizuho, Raymond James, Royal Bank of Canada, Stephens, StockNews.com, TheStreet, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for EHC.

What is the current price target for Encompass Health?

10 Wall Street analysts have set twelve-month price targets for Encompass Health in the last year. Their average twelve-month price target is $69.00, suggesting a possible upside of 27.5%. Truist Financial Co. has the highest price target set, predicting EHC will reach $75.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $57.00 for Encompass Health in the next year.
View the latest price targets for EHC.

What is the current consensus analyst rating for Encompass Health?

Encompass Health currently has 1 hold rating, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EHC will outperform the market and that investors should add to their positions of Encompass Health.
View the latest ratings for EHC.

What other companies compete with Encompass Health?

Other companies that are similar to Encompass Health include Select Medical, Prometheus Biosciences, Halozyme Therapeutics, Globus Medical and The Ensign Group. Learn More about companies similar to Encompass Health.

How do I contact Encompass Health's investor relations team?

Encompass Health's physical mailing address is 3660 Grandview Pkwy Ste 200, BIRMINGHAM, AL 35243-3332, United States. The company's listed phone number is (205) 967-7116 and its investor relations email address is [email protected] The official website for Encompass Health is www.healthsouth.com. Learn More about contacing Encompass Health investor relations.